Two molecules, one extra receptor
The cleanest way to understand the difference is to count the levers each molecule pulls on the body’s energy budget. Tirzepatide pulls two; retatrutide pulls three. Both hit the GLP-1 receptor (the satiety and glucose-control lever) and the GIP receptor (which modulates insulin and appears to buffer GLP-1 nausea). Retatrutide adds the glucagon receptor, which neither tirzepatide nor semaglutide touches.
That third lever is the whole story. Glucagon activation raises hepatic energy expenditure through lipid oxidation — it works on the spending side of the ledger rather than the appetite side. The full receptor-by-receptor breakdown is in our retatrutide mechanism reference.
The head-to-head numbers
| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptors | GLP-1 / GIP (dual) | GLP-1 / GIP / glucagon (triple) |
| Reported weight change | ≈ −22.5% (SURMOUNT-1) | −24.2% at 48 wk (NEJM 2023); largest Phase 3 result on record (TRIUMPH-1, 2026) |
| Status | Approved (Mounjaro / Zepbound) | Investigational — launch ~2028 |
| Dosing in trials | Weekly subcutaneous, titrated | Weekly subcutaneous, titrated (1–12 mg arms) |
A caveat worth stating plainly: these come from different trials with different populations and endpoints, so the percentages are not a clean race. But the mechanistic logic and the published direction agree — the triple agonist reports the larger effect, and the glucagon arm is the reason.
Beyond the weight number
Post-hoc analysis of the retatrutide Phase 2 data reported lower triglycerides (≈ −30%), reduced systolic blood pressure (≈ −7 mmHg) and improved glycemic markers — consistent with the glucagon-driven shift in how energy is handled, not just appetite suppression. Coskun et al. (Cell Metabolism, 2022) also tied the glucagon component to up to an 80% drop in liver-fat content in mouse models, which is why retatrutide draws separate interest in hepatic-steatosis research.
Why this comparison is everywhere right now
Two 2026 events put this matchup at the center of the conversation. The FDA moved to close large-scale GLP-1 compounding, removing the cheap route to tirzepatide, while retatrutide’s record Phase 3 readout landed at the same time — yet it remains years from a pharmacy. The result is a lot of people comparing a molecule they can no longer get cheaply with one they cannot get at all yet. For how coverage and cost actually break down, see our NHS access and cost guide.
The research framing
Both molecules are discussed here strictly as research compounds. Tirzepatide is an approved medicine and is not sold here as a product; retatrutide is available only as a lyophilized research reagent labeled "not for human or animal use." Nothing on this page is dosing or medical guidance. For purity standards and how to read a Certificate of Analysis, the complete research peptides guide is the foundation reference.